Membranoproliferative glomerulonephritis (MPGN) denotes a general pattern of glomerular injury characterized by an increase in mesangial cellularity and matrix with thickening of glomerular capillary walls secondary to subendothelial deposition of immune complexes and/or complement factors, cellular entrapment, and new basement membrane formation. This pattern of injury is easily recognized by light microscopy, making the diagnosis of MPGN relatively straightforward; however, immunofluorescence (IF) and electron microscopy (EM) resolve differences among MPGN that have led to the adoption of classification systems to subgroup MPGN types. Subgrouping is driven by an effort to better understand this diverse spectrum of diseases under the presumption that histologically driven subclassification is reflective of pathogenic similarities, which may have bearing on directing clinical care.
Applying EM to MPGN resolves electron-dense deposits relative to the glomerular basement membrane, such as subendothelial, intramembranous (within the lamina densa), or both subendothelial and subepithelial. These distinctions are classically referred to as MPGN type I (MPGN I), MPGN II, and MPGN III, respectively. [1] [2] [3] [4] Immunofluorescence studies to detect proteinaceous deposits in MPGN will typically reveal immunoglobulins (usually IgG or IgM) in MPGN I and MPGN III, whereas MPGN II is noteworthy because of their absence. Although the three MPGN types stain positive for complement component 3 (C3) consistent with complement activation, as early as the 1970s it was observed that C3-positive but immunoglobulin-negative examples of MPGN I and MPGN III exist. 5 Together with MPGN II, which is appropriately called dense deposit disease (DDD; reviewed in ref. 6 ), this group of C3-positive Ig-negative glomerular diseases has been labeled as C3 glomerulopathies (C3G; Figure 1a ). 7, 8 MPGN-based and C3G-based classifications overlap because their fundamental perspectives differ: the MPGN classification is based on EM, whereas the C3G classification is based on IF microscopy. This overlap is the source of unnecessary confusion, which we will address in this review by focusing on the pathophysiology, evaluation, and treatment of these diseases in the context of a simplified classification ( Figure 1b) . Four illustrative cases are also described. Because the complement cascade is integral to both MPGN and C3G, we will begin by briefly reviewing this aspect of innate immunity.
THE COMPLEMENT CASCADE
The complement system is the cornerstone of innate immunity and its linchpin is C3. The three initiating pathways of complement activation-the classical (CP), lectin (LP), and alternative (AP)-all converge in a cascade manner on this molecule to generate an enzyme complex called C3 convertase that cleaves C3 into C3a and C3b. C3a is a potent pro-inflammatory mediator, whereas C3b is a potent opsonin and a metastable building block from which additional C3 convertase is made, creating a powerful amplification loop. Newly generated C3b interacts with nearby organisms and basement membranes, leading to C3 convertase formation on these surfaces. The association of C3b with C3 convertase also generates C5 convertase, initiating the terminal complement complex (TCC), which terminates in the assembly of the membrane attack complex (MAC) on cell surfaces leading to cell lysis ( Figure 2) .
Numerous proteins regulate complement activity to prevent untoward host damage. Broadly divided into fluidphase (proteins in the circulation) and surface-phase (proteins bound to cell membranes) regulators, these proteins generally modulate the activity of the C3 and C5 convertases. Examples of fluid-phase regulators include C1INH (C1 inhibitor) and C4BP (C4-binding protein), which regulate the CP, and complement Factor H (CFH) and CFI, which regulate the AP. Examples of surface-phase complement regulators include membrane-bound proteins such as CR1 (complement receptor 1, CD35), CD55 (decayaccelerating factor, DAF), CD46 (membrane cofactor protein, MCP), CD59, and CRIg (complement receptor of the immunoglobulin superfamily, also known as VSIG4 (V-set and Ig domain-containing 4)). Clusterin, vitronectin, and CFHR1 (complement Factor H-related 1) regulate the TCC. Several fluid-phase regulators including CFH, clusterin, vitronectin, CFHR1, and C4BP can also attach to cells and biomembranes, adding an additional protective layer in these surfaces to limit active complement products. 9 The interaction between complement activators and regulators is complex yet subtle. Perturbation of this balance Table 2 , light microscopy). Two or more adjacent IgG antibodies provide the structural framework for activation of C1, which cleaves C2 and C4 to generate C2a and C4b, respectively. These two proteins form the CP C3 convertase. The AP is constitutively active, a process that is referred to as 'tick over'. Binding of complement factor (CF)B, CFD, and properdin to hydrolyzed C3 or to C3b leads to formation of the AP C3 convertase C3bBb. This process also generates C3a, a potent anaphylatoxin. When an additional C3b molecule associates with C3 convertase, C5 convertase is formed, initiating the terminal complement complex (TCC) and leading to the generation of membrane attack complex (MAC). Fluid-phase regulators of the CP include C4BP and C1INH, and of the AP, CFH, and CFI (shown in yellow rectangles).
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provides the molecular foundation for understanding C3G. How dysregulation of the C3 and C5 convertases and uncontrolled activity of the AP and TCC lead to C3G is discussed next.
PATHOPHYSIOLOGY Immune complex-associated MPGN
Immune complex-associated MPGN (MPGN I and III in Figure 1a ) is driven by chronic antigenemia or circulating immune complexes (Figure 1b) . In 'idiopathic' or 'primary' MPGN, a causal etiology cannot be found, whereas in 'secondary' cases the associated systemic disease or infection is known. As a general rule, the term 'idiopathic' MPGN should be used infrequently as the underlying reason for antigenemia can be found in most cases. 8 Immune complex-associated MPGN in the adult population is most commonly due to antecedent hepatitis B or C viral infection that drives persistent antigenemia and immune complex formation. In addition to other viruses, infectious causes of MPGN also include those of bacterial origin such as shunt nephritis and infective endocarditis, and protozoal diseases such as malaria and schistosomiasis. MPGN can also result as a complication of circulating immune complexes associated with autoimmune diseases such as mixed cryoglobulinemia, systemic lupus erythematosus, Sjögren's syndrome, and scleroderma. Finally, deposition of monoclonal immunoglobulins in the mesangium and along the glomerular capillary walls is another important cause of immune complex MPGN, and can occur in the setting of monoclonal gammopathy of undetermined significance, chronic lymphocytic leukemia, low-grade B-cell lymphomas, and multiple myeloma (Table 1) . 8, 10, 11 Immune complexes activate the CP triggering an acute injury in the glomerular capillaries and mesangium with influx of inflammatory cells that gives rise to proliferative glomerular changes. The reparative glomerular response is characterized by endothelial and mesangial cell generation of neo-basement membranes, which trap immune complexes, thus forming double contours. Mesangial expansion also occurs because of an increase in mesangial cells, infiltration of mononuclear cells, and increase in mesangial matrix. In concert, these changes make the glomerular tufts appear hyperlobulated. The proportion of cells to matrix varies with disease duration and time. Chronicity is associated with the development of nodular mesangial sclerosis and well-formed double contours with a concomitant decrease in cellularity.
C3 glomerulopathy
C3G is caused by dysregulation of the AP and TCC (Figures 2  and 3 ). Over the past few years, our understanding of this group of diseases has rapidly advanced largely through detailed genetic studies of animal models and a few human families that segregate this type of renal injury. We highlight three of these familial studies as they provide unique insights into C3G. . The prototypic example is dense deposit disease (DDD), in which there must be fluid-phase dysregulation of the C3 convertase, often with dysregulation of the C5 convertase. Dysregulation of the C3 convertase results in increased serum levels of complement factor (CF)I-generated iC3b, which accumulates in the glomerular basement membrane as the characteristic sausage-shaped dense deposits. C3b breakdown products are also detectable in plasma as C3c and C3d. Some patients with C3G also have elevated serum levels of sMAC. Why dysregulation of the AP and TCC leads to DDD in some patients and to C3 glomerulonephritis (C3GN) in others is not understood at this time. However, genetic evidence suggests that a contributing factor may be the relative degree of dysregulation of the C3 and C5 convertases. For example, in the family described by Martínez-Barricarte et al. 12 , there is dysregulation of C3 convertase but not of C5 convertase. Clarifying the differences between DDD and C3GN is likely to be germane to the treatment of these diseases as the availability of anti-complement therapies is currently limited to eculizumab, an anti-C5 monoclonal antibody (shown as a red *) that prevents cleavage of C5 to C5a and C5b, thereby preventing propagation of the TCC.
In 2010, Martínez-Barricarte et al.
12 identified a small nuclear family in which a mother and her two identical twin boys segregated a two-amino-acid deletion in MG7 of C3(D923-924AspGly). This mutant form of C3 was resistant to cleavage by C3 convertase, and therefore could not form activated C3b. However, through the normal 'tickover' process, which forms a hydrolyzed C3 convertase, the mutant C3 protein did form C3 D923À924DG convertase. This convertase was capable of cleaving circulating wild-type C3 translated from the normal (non-mutated) allele but was resistant to CFHmediated regulation. As a consequence, the phenotype in these three people was one of persistent fluid-phase mutant C3 convertase activity, and at the level of the renal glomerulus, the picture was one of classic DDD. The mother and one twin progressed to end-stage renal disease, which was treated in the mother with three transplants, the last still functioning after 3 years, although in the face of microhematuria, proteinuria, and progressing renal insufficiency. The second twin has not yet progressed to end-stage renal disease. Importantly, both accelerated decay of the mutant C3 convertase by CD55 and CD46 cofactor activity for CFI are not affected by the two-amino-acid deletion, providing conclusive evidence that DDD in this family results exclusively from fluid-phase AP dysregulation (Figure 3) .
A second genetic cause of C3G was recently reported by Gale et al. 13 These investigators identified two families segregating autosomal dominant microscopic hematuria. Both families originated from the Troodos mountain region of Cyprus, suggesting an ancestral founder effect. Renal biopsy was remarkable for variable glomerular inflammation in association with subendothelial and mesangial electrondense deposits positive by IF for C3. Genome-wide linkage analysis localized the genetic abnormality to chromosome 1q31-32, a region that includes CFH and the CFHR genes. Using multiplex ligation-dependent amplification, the authors identified a nonhomologous allelic recombination event that resulted in the duplication of CFHR5 to create a novel CFHR5 fusion gene.
CFHR5 is a 65-kDa plasma protein that consists of nine short consensus repeat (SCR) domains. The nonhomologous allelic recombination event in these Cypriotic families creates a larger CFHR5 protein in which its first two SCRs are duplicated to generate a genetic rearrangement that is translated into an 11-SCR novel CFHR5 protein (CFHR5   1,2,1,2,3-9 ). The plasma concentration of CFHR5 is approximately 3-6 mg/ml or B1% that of CFH, and although its precise physiological role is not known, it does colocalize with complement in diseased glomeruli and can associate with surface-bound C3 (C3b) to inhibit C3 convertase activity. [14] [15] [16] Functional studies with the mutant CFHR5 1,2,1,2,3-9 protein showed that it was less effective than wild-type CFHR5 in associating with surface-bound C3b, suggesting a dominantnegative mechanism of action. 13 This finding also highlights the importance of CFHR5 in complement processing within the kidney, a role that is further supported by the identification of CFHR5 mutations in some patients with DDD. 17 The third family was reported by Habbig et al., 18 who described two siblings of consanguineous parentage with childhood-onset hematuria and proteinuria. Detailed complement studies showed serum decreases in C3 and CFB, although C4 was normal and C3d was increased. Renal biopsy was remarkable for prominent mesangial deposition of C3 and C5b-9, and by EM there were numerous osmiophilic mesangial deposits with intramembranous and subendothelial roundish glomerular basement membrane deposits. Mutation screening of CFH showed that both children were homozygous for the deletion of a single amino acid, lysine, at position 224 (CFH K244). This deletion affects SCR4 of CFH and leads to defective complement control by severely reducing cofactor, decay accelerating activity and C3b binding. 19 Cell-binding activity, however, remains normal. Because the typical linear hyperosmiophilia of DDD was absent, the authors proposed calling this pattern of injury C3 deposition glomerulopathy (C3DG).
In aggregate, these familial cases suggest that C3G is a disease spectrum that is dependent on the level and degree of dysregulation of the AP and TCC. In most cases of DDD and C3 glomerulonephritis (C3GN), however, the family history is negative, making the identification of risk factors, whether genetic or acquired, a challenge. It is possible, for example, that allele variants of membrane-bound complement regulators may affect the disease phenotype, a hypothesis that warrants testing. In addition, more in-depth studies are needed to determine whether specific biomarkers of complement activity can be used to differentiate DDD from C3GN and predict response to therapy. Finally, efforts should be made to clarify the biological role of CFHR5 and the other CFHR proteins in normal and disease renal physiology.
EVALUATION AND TREATMENT Immune complex-associated MPGN
The evaluation of immune complex-associated MPGN should focus on identifying the underlying triggering disease in order to begin appropriate disease-specific treatment ( Table 1 ). The cornerstone of therapy in this setting is often an anti-cell proliferation agent such as a calcineurin inhibitor, mycophenolate mofetil, cyclophosphamide, or rituximab. 20 In many patients, evaluation of the complement system will often show evidence for activation of the CP, with decreased serum levels of C3 and C4, and an abnormal CH50. Whether anti-complement drugs will be complementary to anti-proliferative agents in this setting has not been explored. In a small subgroup of immune complex-associated MPGN, it may be impossible to determine the origin of the deposited Ig. These cases should be labeled 'idiopathic' MPGN. There may also be a small subset of immune complex-associated MPGN that demonstrates concurrent AP abnormalities. It is important to point out that, in such cases, the deposition of immune complexes in the glomeruli drives the disease process, and it is imperative to carry out investigations to determine the etiology of the deposited immunoglobulins. Little data exist on the long-term consequences of C3GN. Servais et al. 21 reported on a series of 19 patients with C3GN. Median age at onset was 29.9 years (range 7-70 years) and median follow-up age was 12.3 years (range 0.4-34.0 years). At the time of the study, three patients had progressed to end-stage renal disease and required dialysis, whereas six additional patients had substantial renal dysfunction, with creatinine clearances of less than 60 ml/min. Although these outcomes are based on limited data, they do suggest that, although the prognosis for C3GN may be poor, it carries a better prognosis than DDD. More than half of DDD patients progress to end-stage renal disease within 10 years of diagnosis, and when transplanted face the dismal reality of near-universal disease recurrence leading to a 5-year allograft failure rate of 50%. 22 The outlook for either C3GN or DDD is unlikely to change until disease-specific treatments become available. Following a biopsy consistent with C3G, most patients should be placed on angiotensin II type 1 receptor blockers or angiotensin-converting enzyme inhibitors to improve renal dynamics, decrease proteinuria, control blood pressure, and limit glomerular leukocyte infiltration. 22, 23 All patients should undergo targeted studies to evaluate the AP by measuring serum complement levels (C3, C4, CH50, AH50), complement breakdown products (C3c and sMAC), and disease-associated autoantibodies such as C3 nephritic factors and autoantibodies to CFH and CFB. Genetic testing is also indicated and, at a minimum, should include CFH, although several other genes have also been implicated in C3GN and DDD. 6, 24 Mutations in CFH are also associated with atypical hemolytic uremic syndrome, where they tend to cluster in the last two SCRs of the protein and affect its ability to regulate cell membrane-bound C3 convertase. 25 The pathophysiology of C3G suggests that a number of different treatments should be considered. For example, in the family described by Habbig et al., 18 CFH replacement is likely to be beneficial. It is possible that additional CFH may also help in the Cypriotic form of C3GN. Importantly, although CFH replacement is currently available only through plasma exchange, pharmaceutical preparations may be available for therapeutic use in the near future. 26, 27 It is equally clear, however, that exogenous CFH would be of no benefit to DDD patients with the C3 D923DG mutation reported by Martínez-Barricarte et al., 12 as the mutant C3 convertase is CFH resistant. For these patients, specific treatment options that restore C3 convertase control, impair C3 convertase activity, or remove C3 breakdown products from the circulation are required but remain to be developed.
The benefit of targeting MAC is more difficult to assess, as the role of C5 activation and C5 convertase dysregulation in the pathogenesis of C3G requires further investigation. There are, however, C3GN patients with elevated plasma levels of sMAC who would be predicted to benefit from eculizumab, a monoclonal antibody that blocks C5 activation (and therefore MAC production) and is approved for the treatment of paroxysmal nocturnal hemoglobinuria ( Figure 3) . 28 Although eculizumab also appears to be a very effective therapy for atypical hemolytic uremic syndrome, 29 its use in C3GN patients needs careful consideration. Certainly, it seems unlikely that patients such as those reported by Martínez-Barricarte et al. 12 would gain much benefit from C5-inhibiting strategies, except perhaps during secondary triggers of complement activation (such as infections) that may lead to acute disease exacerbation.
ILLUSTRATIVE CASES Case 1
Case 1 showed an MPGN pattern on LM (Figure 4 ). By IF, there was predominant IgM and C3 staining in the mesangium and capillary walls. There was also staining for both kappa and lambda light chains. EM studies showed subendothelial deposits with double contour formation. Further evaluation confirmed hepatitis C infection. Diagnosis: membranoproliferative glomerulonephritis secondary to hepatitis C.
Case 2
Case 2 showed an MPGN pattern on LM ( Figure 5) . A small cellular crescent was also noted. IF studies showed staining for IgG, C3, and kappa light chains along the capillary walls; lambda light chains were negative. EM studies show subendothelial deposits with double contour formation. Further evaluation showed monoclonal IgG kappa on immunofixation studies and 5% plasma cells on bone marrow biopsy. Diagnosis: membranoproliferative glomerulonephritis secondary to monoclonal IgG kappa.
Case 3
Case 3 showed an MPGN pattern on LM ( Figure 6 ). IF studies were strongly positive for C3 in the mesangium and along capillary walls, but were negative for IgG, IgM, IgA, C1q, and kappa and lambda light chains. EM studies showed numerous subendothelial and mesangial deposits with double contour formation. A few intramembranous and occasional subepithelial deposits were also noted. Evaluation of the AP identified antibodies to Factor H. Diagnosis: C3GN: membranoproliferative glomerulonephritis secondary to AP dysfunction caused by anti-Factor H antibodies.
This case is noteworthy because the differential diagnosis of C3GN includes postinfectious GN, particularly the so-called resolving/healing postinfectious GN characterized by the presence of subepithelial humps ( Table 2 ). The absence of any history of infection anteceding the development of GN, the bright C3 staining, and the absence of immunoglobulins on IF should raise the possibility of C3GN. EM is also helpful in that C3GN typically shows large subendothelial and mesangial deposits; intramembranous and subepithelial deposits were also often noted. The deposits are lighter and have a fuzzy lobular appearance as compared with the darker and sharper immunoglobulin-containing deposits of postinfectious GN.
Case 4
Case 4 showed an MPGN pattern on LM (Figure 7) . IF studies were positive for C3 in the mesangium and along capillary walls, but negative for IgG, IgM, IgA, C1q, and kappa and lambda light chains. EM studies showed dense deposits along Immunoglobulin-positive MPGN is driven by chronic antigenemia or circulating immune complexes, and evaluation should focus on identifying the underlying trigger in order to begin disease-specific treatment. The cornerstone of therapy is often an anti-cell proliferation agent, although in many patients evaluation of the complement system will show evidence for activation of the CP, with decreased serum levels of C3 and C4, and an abnormal CH50. The evaluation of C3G, in contrast, should focus on the alternative complement cascade. Dysregulation of the AP and TCC underlies pathogenesis, although the differences that lead to either a DDD or C3GN pattern of injury are not understood. The concept of anticomplement therapy as a disease-specific treatment for the C3G will require better characterization of this group of diseases.
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